Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Pierre Borczuk who wrote (4810)	8/9/1998 8:40:00 PM
From: Dave	Read Replies (1) \| Respond to of 9523

<<Arava does not seems to be a COX-2 drug...so no comparison to Celebra>> Definitely true... The arthritis market is typically divided between rheumatoid arthritis (RA) and osteoarthritis (OA). While NSAIDs (both COX1 and COX2 inhibitors) can be used in RA, disease modifying drugs (DMARDs - like Arava)are also used, especially as the RA gets progressively worse. These drugs however have some nasty side effects and should be used cautiously. They are not typically used in OA which is where Celebra will make its mark. Also, the RA market in the US runs somewhere around 4MM to 8MM patients depending on who you talk to. The OA market runs more around 20 - 25MM patients, so there is much more opportunity to recoup the R & D investment for a drug in the OA arena. Just my two cents, but Celebra is going to be huge no matter how you cut it. Just a matter of time. Dave